Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis. (16th May 2018)

• Record Type: Journal Article
• Authors: Garcia-Prats, Anthony J; Draper, Heather R; Finlayson, Heather; Winckler, Jana; Burger, André; Fourie, Barend; Thee, Stephanie; Hesseling, Anneke C; Schaaf, H Simon
• Is Part Of: Clinical infectious diseases. Volume 67:Number 11(2018)
• Page Start: 1777
• Page End: 1780
• Publication Date: 2018-05-16
• Subjects: levofloxacin -- safety -- children -- MDR-TB -- QT prolongation; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciy416
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Safety concerns persist for long-term pediatric fluoroquinolone use. Seventy children (median age, 2.1 years) treated with levofloxacin 10–20 mg/kg once daily for multidrug-resistant tuberculosis (median observation time, 11.8 months) had few musculoskeletal events, no levofloxacin-attributed serious adverse events, and no Fridericia-corrected QT interval >450 ms. Long-term levofloxacin was safe and well tolerated.